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Transformed cells are known to differ from their 
normal counterparts in a wide variety of ways, including 
their increased reliance on aerobic glycolysis, defects in 
DNA damage checkpoint controls, diminished reliance 
on growth factors for survival, dysregulation of cell cycle 
control mechanisms, and propensity for dissemination 
beyond their normal environment, among numerous others. 
In 2000, Weinberg described six essential “hallmarks of 
cancer”, providing a theoretical framework for exploiting 
the transformed state from a therapeutic standpoint [1]. 
In 2009, Elledge expanded this list to 12 characteristics, 
including several described as “orthogonal” elements [2]. 
These processes were invoked to explain the paradoxical 
observation that certain oncogenes, such as c-myc, while 
conferring a proliferation advantage on transformed 
cells, may nevertheless exert pro-apoptotic activities. 
Consequently, a second aberration (i.e., up-regulation of 
an anti-apoptotic protein such as Bcl-2) may allow cells to 
escape the otherwise lethal effects of c-myc dysregulation, 
and in so doing, cooperate in transformation [3]. 
Another important “orthogonal” characteristic 
of transformed cells is their capacity to withstand the 
accumulation of un- or misfolded proteins, referred to 
as proteotoxic stress. Neoplastic cells in general exhibit 
increased protein turnover, and certain tumors e.g., 
multiple myeloma, have extremely high turnover rates. 
Ordinarily, such proteins are dealt with by ubiquitination 
and proteasomal degradation by the ubiquitin-proteasome 
system (UPS), and this process is facilitated by the 
induction of a variety of protein chaperones, including 
members of the heat shock protein family (i.e., Hsp90 and 
Hsp70) [4]. Increased accumulation of misfolded proteins 
in the endoplasmic reticulum (ER) can also lead to 
another form of proteotoxic stress referred to as ER stress. 
In this case, the unfolded protein response (UPR) consists 
of various compensatory events, including increased 
synthesis of ER chaperone proteins, shut-down of protein 
synthesis (i.e., by PERK/eIF2α), and accelerated protein 
degradation (ERAD) [5]. Various forms of the proteotoxic 
stress response can play cytoprotective roles at early 
intervals, but when the protein load exceeds a certain 
threshold, they can instead contribute to cellular demise 
[6]. 
The increased reliance of transformed cells on 
systems that ameliorate the deleterious effects of 
proteotoxic stress has stimulated the development of 
multiple  strategies  and  agents  specifically  designed  to 
disable these mechanisms. For example, intense efforts 
have been directed at developing inhibitors of Hsp90, and 
several such agents i.e., geldanamycin and more current 
derivatives such as DMAG, have now entered the clinical 
arena [7]. Furthermore, the observation that Hsp90 
antagonists stimulate the HSF1-dependent induction of 
Hsp70, and that the latter protein can protect transformed 
cells from Hsp90 inhibitor-mediated lethality, has 
prompted the development of Hsp70 antagonists, to be 
used either alone or possibly in combination with Hsp90 
inhibitors [8]. However, the greatest success to date with 
this group of compounds is that of inhibitors of the 26S 
proteasome such as bortezomib, which among numerous 
actions, block protein degradation and in so doing, 
promote the accumulation of misfolded proteins [9]. 
Notably, bortezomib has been approved for the treatment 
of refractory mantle cell lymphoma, as well as relapsed 
multiple myeloma, a disease characterized by pronounced 
protein turnover.    
Not surprisingly, attempts to combine these strategies 
in the hope of exceeding the proteotoxic stress threshold 
and triggering cell death have attracted considerable 
attention. For example, preclinical studies have shown 
that simultaneously disrupting Hsp90 function (i.e., 
with Hsp90 antagonists) and interfering with protein 
degradation (i.e., by proteasome inhibitors) markedly 
increases transformed cell death [10], and attempts to 
translate this strategy into the clinic are currently underway. 
Similarly, evidence that Hsp70 induction can compensate 
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combining Hsp90 and Hsp70 inhibitors, and this approach 
has also been found to potentiate neoplastic cell death [8]. 
In this context, interest has recently focused on HDAC 
inhibitors as potential modulators of the proteotoxic 
stress response. For example, it has been shown that 
inhibition of HDAC6 leads to disruption of the dynein 
motor responsible for the normal function of aggresomes, 
which are intimately involved in regulating the proper 
disposition and subsequent elimination of misfolded 
proteins [11]. The ability of pan-HDAC inhibitors, which 
target HDAC6, to disrupt aggresome function has been 
invoked to explain their potentiation of the antitumor 
activity of bortezomib i.e., in multiple myeloma cells 
[12]. In some cells e.g., mantle cell lymphoma cells, this 
interaction may also involve shifting of the ER stress 
response from a cytoprotective to a pro-apoptotic process 
[13]. 
To date, most approaches attempting to exploit 
proteotoxic stress from a therapeutic standpoint have 
focused on combining agents that disable different 
components of the proteotoxic stress response e.g., 
chaperone proteins and proteasome function. However, 
results of a study by Neznanov et al., recently reported 
in Oncotarget [14] suggest a fundamentally different 
approach to this problem. Neznanov and colleagues 
employed the proteasome inhibitor bortezomib to 
enhance proteotoxic stress of transformed cells subjected 
to interventions that by themselves increased the cell’s 
burden of misfolded proteins i.e., hyperthermia or the 
antibiotic puromycin, which causes premature termination 
of translation leading to the accumulation of misfolded 
proteins. These investigators found that combined 
treatment of transformed cells with hyperthermia or 
puromycin with bortezomib, at exposures that were 
minimally toxic individually, resulted in a marked increase 
in protein ubiquitination and cell death. Notably, lethality 
occurred despite the marked induction of HSF-1-mediated 
induction of the cytoprotective chaperone protein Hsp70. 
In addition, while intact p53 function was not required for 
cell death induced by this strategy, its presence resulted in 
an increase in lethality. Importantly, the combination of 
puromycin and bortezomib resulted in enhanced antitumor 
activity in a murine xenograft model, suggesting that this 
phenomenon is not restricted to the in vitro setting. 
The results of this study have potentially important 
implications, including those that are translational in 
nature. Currently, considerable interest has focused on 
targeting those pathways to which transformed cells 
are either addicted [15] and/or uniquely reliant due 
to enhanced tumor cell requirements e.g., handling 
of increased protein turnover or DNA damage [16]. 
However, it has become increasingly apparent that with 
rare exceptions, interruption of a single pathway or 
process is unlikely to have a major benefit in of itself; 
instead, interruption of multiple complementary pathways 
may be necessary [17]. In the case of proteotoxic stress, 
past and current approaches have understandably involved 
the rational combination agents that disrupt various 
cellular mechanisms designed to cope with this problem 
e.g., proteasome and chaperone protein antagonists. It 
is presumed that the inherent reliance of tumor cells on 
such protein disposal mechanisms should be sufficient to 
ensure adequate antitumor activity of these strategies. The 
implications of the report by Neznanov et al., are that this 
assumption may not be justified i.e., simply disrupting 
the proteotoxic stress response at multiple sites may not 
be sufficient for significant therapeutic benefit, even in 
those transformed cells known exhibit increased protein 
turnover. Instead, interventions that increase the cell’s 
burden of misfolded proteins, including hyperthermia or 
disruptors of translation, may represent superior candidates 
for combination with proteasome inhibitors (or possibly 
other agents that interfere with protein disposition) in the 
clinical setting. In this context, a variety of agents known 
to block protein translation (e.g., ribavarin, sorafenib) 
deserve scrutiny [18, 19]. Questions remaining to be 
addressed include determining whether such strategies 
do in fact selectively target transformed cells, assessing 
whether the benefit of these strategies will be restricted 
to neoplastic cells characterized by high protein turnover, 
and identifying optimal regimens combining agents 
that promote proteotoxic stress with those that disrupt 
protein disposition. It is anticipated that answers to these 
questions may be forthcoming at both the preclinical and 
clinical levels in the years to come.
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